Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Breast. 2023 Dec 22;73:103667. doi: 10.1016/j.breast.2023.103667. Online ahead of print.ABSTRACTAntiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.PMID:38160476 | DOI:10.1016/j.breast.2023.103667

Source: Breast - December 31, 2023 Category: Cancer & Oncology Authors: Yasmine Rhanine Herv é Bonnefoi Anthony Goncalves Marc Debled Sylvestre Le Moulec Nathalie Bonichon Gaetan Macgrogan Monica Arnedos B énédicte Dubroca-Dehez Thomas Grellety Source Type: research